



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**

**-or-**  
**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT ANNOUNCES ANCESTRY TESTING PROGRAM  
FOR DENTAL PATIENTS**

**SARASOTA, Fla., June 22, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced an innovative new program that will enable dentists to offer DNA testing to patients who want to explore their family heritage.

AncestrybyDNA™ test kits and marketing materials will be made available to participating dentists who will be able to provide DNA sampling in a hygienic environment. Once the samples have been taken with a mouth swab, the dentists will forward them to DNAPrint for analysis. Confidential test results will be sent directly to patients from DNAPrint laboratories.

“We believe the professional, safe and trusted environments of dentists’ offices lend themselves perfectly to DNA sampling and test result confidence,” said DNAPrint President and Chief Executive Officer Richard Gabriel. “We hope this program encourages individuals to explore their family histories through genetic testing.”

An attractive pricing plan, free marketing materials and an offer of additional and more comprehensive DNAPrint genealogy tests are additional features of the program.

Mr. Gabriel said that those who choose to have their DNA sampled can be assured that the results are secure and confidential. In a recent interview on National Public Radio’s News & Notes, Mr. Gabriel noted DNAPrint Genomics’ well-established position concerning privacy for those taking DNA tests to determine their ancestry. “We protect information (we get) from individuals and don’t use it in any other way,” he said. “If (our customers) want it destroyed, we destroy it. It’s not ours or anyone else’s. We believe this very strongly.”

DNAPrint applies its proprietary DNA technology in three business segments. Its pharmacogenomics subsidiary develops test/drug combinations (“theranostics”), which are designed to increase drug efficacy and reduce side effects. DNAPrint’s forensics subsidiary applies its DNAWitness™ technology for law enforcement agencies and criminal investigations, and the Company’s genealogy subsidiary markets its AncestrybyDNA family of products to help people explore their family heritage.

**About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company’s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company’s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and

(MORE)

clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWitness (TM), RETINOME(TM), AncestrybyDNA(TM) and EuroDNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

### **Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###